Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trifluoperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.82 |
| ▸ | FPR2 | P25090 | 11/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | RAD52 | P43351 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoperazine SCHEMBL29603012 | 1.00 | FPR2 (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL24866 | 1.00 | FPR2 (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL29430171 | 0.99 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL41194 | 0.99 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL29579627 | 0.99 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL23039392 | 0.99 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL341516 | 0.99 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL466955 | 0.98 | FPR2 (0.96) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL21445272 | 0.98 | FPR2 (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL28329317 | 0.95 | FPR2 (0.90) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2012163990-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS TREATED WITH NEUROLEPTIC AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | WO | disclosed |
| WO-2011059547-A2 | CRYOPRESERVATION OF CELLS AND SUBCELLULAR FRACTIONS | XENOTECH, LLC (US) | 2011-05-19 | — | — | WO | disclosed |